CN Patent

CN114945366B — Hpk1拮抗剂和其用途

Assigned to Limbers Sutton Co · Expires 2025-01-07 · 1y expired

What this patent protects

本发明提供用于抑制HPK1和治疗HPK1介导的病症的化合物、其组合物以及使用其抑制HPK1和治疗HPK1介导的病症的方法。

USPTO Abstract

本发明提供用于抑制HPK1和治疗HPK1介导的病症的化合物、其组合物以及使用其抑制HPK1和治疗HPK1介导的病症的方法。

Drugs covered by this patent

Sotyktu (DEUCRAVACITINIB) · Bristol-Myers Squibb

Patent Metadata

Patent number: CN114945366B
Jurisdiction: CN
Classification: —
Expires: 2025-01-07
Drug substance claim: No
Drug product claim: No
Assignee: Limbers Sutton Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.